In a research note titled "Hard To Ignore All The Positive Developments Coming Out of VRX," Cantor Fitzgerald analyst Louise Chen says the FDA's intention to issue a Voluntary Action Indicated inspection classification for the company's Bausch + Lomb manufacturing facility in Tampa is good news. The development should facilitate the approval of new drugs manufactured out of this facility, Chen tells investors in a research note. She points out that the FDA did not identify any efficacy or safety concerns with respect to the new drug application for Vyzulta, or additional clinical trials needed for the approval. The analyst thinks Vyzulta has the potential to be a blockbuster drug and that manufacturing uncertainties related to current and upcoming regulatory submissions should be eliminated for products manufactured at the Tampa facility. Chen has an Overweight rating on Valeant with a $23 price target. The drugmaker closed yesterday at $14.15.